Submitted via Portfolio Armor:
Meet The New Number Two
In our previous post (Tim Scott's Shady Campaign Spending), we looked at some anomalous spending on shell companies by the GOP candidate currently in 3rd place in Iowa and New Hampshire, Senator Tim Scott of South Carolina.
Shedding light on the Senator and Presidential candidate's mysterious millions.https://t.co/ALiGx9dIJx— Portfolio Armor (@PortfolioArmor) August 8, 2023
As we wrote there, Scott is worth paying attention to because he has been mooted as a possible Trump running mate. The same is true of rising star Vivek Ramaswamy, who just climbed past Florida Governor Ron DeSantis to become the second most popular GOP Presidential candidate after Donald Trump.
2024 National Republican Primary— InteractivePolls (@IAPolls2022) August 10, 2023
Trump 53% (+1 from May)
Ramaswamy 11% (+6)
DeSantis 10% (-11)
Pence 6% (+2)
Scott 3% (+1)
Haley 3% (-2)
Suarez 1%@cygnal (A) | LVs | August 1-3https://t.co/FWWoX5v5E5 pic.twitter.com/rpdDEwInvG
Unlike DeSantis, Ramaswamy has proved to be an excellent campaigner, and apparently, the more GOP voters see of him, the more they like him. But a recent analysis of his pharma career raises some questions about him.
Making Money Marketing A Failed Alzheimer's Drug
The video below, by Kevin Paffrath, details how Vivek Ramaswamy made money off of a failed Alzheimer's drug. In a nutshell:
- Ramaswamy's parent company (Roivant) spent $5 million (a tiny amount, by biotech standards) buying the rights to a drug candidate for Alzheimer's disease from GSK, plc (the former GlaxoSmithKline) that had failed four out of four clinical trials, and formed a subsidiary company around it called Axovant.
- Ramaswamy's mother (a physician) took one of the failed clinical trials and reinterpreted it, by eliminating patients who didn't stay with the trial (because of side effects, the drug not working, or whatever), claiming there was some statistical benefit to the drug.
- Ramaswamy brought Axovant public, raising $362 million in its IPO, for a drug Paffrath claims Ramaswamy knew would fail its stage three clinical trial.
- The drug failed, and Axovant (now called Sio Gene Therapies) is down 99.75% from its IPO.
Ramaswamy's Team Responds
On X (Twitter), Ramaswamy's deputy communications director Stefan Mychajliw responded to Kevin Paffrath's video with the post below.
Not really:— Stefan Mychajliw (@StefanMychajliw) August 6, 2023
Exposing Democrat @realMeetKevin;
* Being sued for $1 billion
* Paid to pump up @FTX_Official before its collapse. 🤔
* People lost their life savings.
* Paid to promote a guy charged with eight federal counts of defrauding customers, laundering money, and violating…
Kevin Paffrath Strikes Back
In response to Vivek's staffer's tweet, Paffrath posted another video,
But the gist of it is this slide, pointing out that Vivek's deputy comms director didn't respond to any of Paffrath's substantive claims, and instead just made ad hominem attacks on Paffrath.
It will be interesting if an increasingly desperate DeSantis brings this up at the first GOP debate, but given the incompetence of DeSantis's campaign team so far, I doubt they even know about this.
In Case You Missed It
On our trading Substack, we placed an options trade on another under-the-radar energy company, after our recent success with Evolution Petroleum (EPM).
Unlike Axovant, we don't have to worry about whether their product works or not. If you'd like a heads up when we place our next trade, feel free to subscribe to our trading Substack/occasional email list below.
If You Want To Stay In Touch
You follow Portfolio Armor on Twitter here, or become a free subscriber to our Substack using the link below (we're using that for our occasional emails now). You can also contact us via our website. If you want to hedge, consider using our website (our iPhone app is currently not available to new users).